Clinical trials: Relapsed/Refractory Diffuse Large B Cell Lymphoma
- Condition Relapsed/Refractory Diffuse Large B Cell Lymphoma
- Funder type Industry (pharma, biotech, devices)
Relapsed or Refractory Diffuse Large B-Cell Lymphoma
A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)
The purpose of this study is to evaluate zilovertamab vedotin with respect to objective response rate and duration of response per Lugano Response Criteria as assessed by blinded independent central review (BICR).
- Trial name
- NCT05144841
- Testing
- Zilovertamab vedotin
- Where
- 71 sites in United States, Canada and 15 more
- Volunteers
- 140 people
- Sponsor
- Merck Sharp & Dohme LLC
Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL)
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
The drug that will be investigated in the study is an antibody, GEN3014. Since this is the first study of GEN3014 in humans, the main purpose is to evaluate safety.
- Conditions
- Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)
- Trial name
- NCT04824794
- Testing
- GEN3014, Daratumumab
- Where
- 52 sites in United States, Australia and 18 more
- Volunteers
- 130 people
- Sponsor
- Genmab
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy.
- Trial name
- LOTIS 5 (NCT04384484)
- Testing
- Loncastuximab Tesirine, Rituximab, Gemcitabine
- Where
- 144 sites in United States, Argentina and 19 more
- Volunteers
- 440 people
- Sponsor
- ADC Therapeutics S.A.
B Cell Lymphoma, NHL, Adult
SynKIR-310 for Relapsed/Refractory B-NHL
This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.
- Conditions
- B Cell Lymphoma, NHL, Adult, Mantle Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
- Trial name
- NCT06544265
- Testing
- SynKIR-310
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Verismo Therapeutics
Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL
To investigate the tolerability and safety of OPB-111077 in combination with bendamustine and rituximab in patients with r/r DLBCL.
- Trial name
- NCT04049825
- Testing
- OPB-111077
- Where
- Japan
- Volunteers
- 36 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib
The goal of this clinical trial was to evaluate whether zanubrutinib can effectively treat adults with CD79B-mutant relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT05068440
- Testing
- Zanubrutinib
- Where
- 25 sites in China
- Volunteers
- 65 people
- Sponsor
- BeiGene
Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma
Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
This is a multi-center, phase I/II study to determine the safety and efficacy of TC011(CD19 Targeted CAR-T) in adult patients with relapsed or refractory large B-cell non -hodgkin lymphoma.
- Conditions
- Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), High-grade B-cell Lymphoma (HGBL)
- Trial name
- TC011 (NCT07473167)
- Testing
- TC011
- Where
- South Korea
- Volunteers
- 98 people
- Sponsor
- TICAROS Co., Ltd.
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
The purpose of this study is to evaluate the safety and preliminary efficacy of ATA3219 in participants with relapsed/refractory (R/R) B-cell non-Hodgkin Lymphoma (NHL).
- Trial name
- NCT06256484
- Testing
- ATA3219
- Where
- 6 sites in United States, Australia
- Volunteers
- 1 people
- Sponsor
- Atara Biotherapeutics
Relapsed or Refractory Lymphoma Including ENKL
A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
This study is a multi-center, global, open-label, Phase 1b/2 clinical study, and it will be conducted at multiple study sites in several countries, including Japan, Korea, and Singapore, to reveal the safety, tolerability, dose…
- Trial name
- NCT06761677
- Testing
- Brincidofovir
- Where
- 8 sites in China, Japan and 1 more
- Volunteers
- 43 people
- Sponsor
- SymBio Pharmaceuticals
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma
The goal of this clinical study is to assess whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in participants with relapsed/refractory diffuse large B-cell…
- Trial name
- ZUMA-7 (NCT03391466)
- Testing
- Axicabtagene Ciloleucel, Platinum-containing Salvage Chemotherapy, Cyclophosphamide
- Where
- 72 sites in United States, Australia and 12 more
- Volunteers
- 359 people
- Sponsor
- Kite, A Gilead Company
Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
This is a Phase 1/2, multicenter, open-label study to evaluate the efficacy, and safety of various combinations with selinexor in participants with RR DLBCL. The study will be conducted in two phases: Phase 1 and 2.
- Trial name
- NCT04607772
- Testing
- Selinexor, Rituximab, Bendamustine
- Where
- 18 sites in United States
- Sponsor
- Karyopharm Therapeutics Inc
Relapsed/Refractory B-cell Malignancies
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: Identify the recommended dose of AC676 that can be given safely to…
- Trial name
- NCT05780034
- Testing
- AC676
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- Accutar Biotechnology Inc
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab
The primary purpose of this study is to assess the safety and tolerability of ociperlimab (BGB-A1217) in combination with tislelizumab (BGB-A317) or rituximab in participants with relapsed or refractory (R/R) diffuse large B cell…
- Trial name
- NCT05267054
- Testing
- Ociperlimab, Tislelizumab, Rituximab
- Where
- 19 sites in China
- Volunteers
- 53 people
- Sponsor
- BeiGene
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma
The purpose of this study is to test the safety and efficacy of AUTO3, a CAR T cell treatment targeting CD19 and CD22 with consolidation or pre-conditioning with anti-PD1 antibody in patients with DLBCL
- Trial name
- ALEXANDER (NCT03287817)
- Testing
- AUTO3
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 52 people
- Sponsor
- Autolus Limited
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
The primary objective of this study is to determine the maximum tolerated doses (MTD) and the recommended Phase 2 dose (RP2D), and safety, tolerability, and efficacy of zanubrutinib in combination with lenalidomide in…
- Trial name
- NCT04436107
- Testing
- Zanubrutinib, Lenalidomide
- Where
- 10 sites in China
- Volunteers
- 66 people
- Sponsor
- BeiGene
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma
This is a prospective, open-label, multi-center clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of firicabtagene autoleucel (firi-cel), a…
- Trial name
- FIRCE-1 (NCT05972720)
- Testing
- Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)
- Where
- 31 sites in United States
- Volunteers
- 101 people
- Sponsor
- CARGO Therapeutics
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This is an open-label, single arm, and registered study of ATG-010 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
- Trial name
- SEARCH (NCT03992339)
- Testing
- ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle
- Where
- 18 sites in China
- Volunteers
- 60 people
- Sponsor
- Antengene Corporation
Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma.
- Conditions
- Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT04305444
- Testing
- DTRM-555
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- Zhejiang DTRM Biopharma
Relapsed/Refractory Aggressive B-Cell Malignancies
A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies
This is a Phase 1/2 study to investigate the safety and efficacy of the CAR-T therapy, ONCT-808, in patients with relapsed/refractory (R/R) aggressive B cell malignancies.
- Trial name
- NCT05588440
- Testing
- ONCT-808, Bridging Therapy
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Oncternal Therapeutics, Inc
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
The primary objective of the study is to determine the maximum tolerated dose (MTD) of blinatumomab in combination with pembrolizumab in adults with relapsed or refractory (r/r) DLBCL.
- Trial name
- HARBOUR (NCT03340766)
- Testing
- Blinatumomab, Pembrolizumab
- Where
- 22 sites in United States, Australia and 4 more
- Volunteers
- 31 people
- Sponsor
- Amgen